Securities adjusted its outlook on Boston Scientific (NYSE:BSX) shares, raising the price target to $130 from $110 while maintaining an Outperform rating. The revision follows a series of positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback